BACKGROUND: Glucose variability combined with glycosylated hemoglobin (HbA1c) assessments more reliably represents the level of glycemic control. The study was aimed to compare blood glucose variability with insulin glargine vs. neutral protamine Hagedorn (NPH) in patients with type 2 diabetes mellitus using a continuous glucose-monitoring system (CGMS), in patients treated with basal insulin using stable dose of oral antidiabetic agents and HbA1c in the range of 4.5-8.0 % International Federation of Clinical Chemistry (IFCC) units. [6.2-9.4 % Diabetes Control and Complications Trial (DCCT) units]. METHODS: This was a multicenter, prospective, open-label, single-arm study in patients (N = 116) treated for ≥ 2 months with NPH and metformin combined with sulfonylurea or glinide. Glucose variability was measured after a 4-week NPH treatment phase and after a subsequent 12-week glargine treatment phase using CGMS. Based on 72-hour CGMS, glucose variability was assessed by area under the curve [AUC (mmol/L · h)]. Differences (glargine-NPH) in AUC within 24 h in the glucose ranges of ≤ 3.3, ≤ 3.9, 7.5-3.9 (margins excluding), ≥ 7.5, ≥ 10, and ≥ 15 mmol/L were evaluated. Circadian fluctuation of glucose was assessed by M-value (log-transformation of the deviation from an arbitrary standard). RESULTS: AUCs of glucose in the lowest ranges (≤ 3.3 and ≤ 3.9 mmol/L) did not change significantly after treatment with glargine. Those in the higher ranges (≥ 7.5, ≥ 10, and ≥ 15 mmol/L) were significantly lower (p < 0.001 for all ranges), whereas AUC of glucose in the normal range (3.9-7.5 mmol/L) was significantly higher (p < 0.001) at the end of glargine treatment phase. Circadian fluctuation of glucose assessed by M-value showed a significant decrease after glargine treatment (p < 0.003). No significant differences in hypoglycemia confirmed by glucose value ≤ 3.3 mmol/L were found between treatment phases. This trial is registered at ClinicalTrials.gov, NCT00659477. CONCLUSIONS: As monitored by CGMS, switching from NPH to glargine with active titration shifted glucose from abnormally high to normal levels with reduced fluctuation and without increased risk of hypoglycemia.

Medical Department 2nd Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

Diabetes Metab Res Rev. 2009 Jul;25(5):393-402 PubMed

Diabetes. 2003 Nov;52(11):2795-804 PubMed

Am Heart J. 2006 Jul;152(1):27-38 PubMed

Diabetes Care. 2000 Aug;23(8):1130-6 PubMed

Diabetes Care. 2000 Jun;23(6):813-9 PubMed

Vasc Med. 2005 Aug;10(3):191-8 PubMed

Diabetes Care. 2008 Jun;31(6):1160-4 PubMed

Diabetes. 2000 Dec;49(12):2142-8 PubMed

Diabetologia. 1996 Dec;39(12):1577-83 PubMed

Lancet. 1998 Sep 12;352(9131):837-53 PubMed

Diabet Med. 2010 Aug;27(8):872-8 PubMed

Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S15-9 PubMed

J Lab Clin Med. 2003 Apr;141(4):242-9 PubMed

Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):353-63 PubMed

J Diabetes Complications. 2005 May-Jun;19(3):178-81 PubMed

See more in PubMed

ClinicalTrials.gov
NCT00659477